Skip to content

Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care

Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03463655
Acronym
AGASA-SP
Enrollment
50
Registered
2018-03-13
Start date
2017-12-21
Completion date
2018-04-30
Last updated
2018-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Cancer in a Palliative Situation With Ascites

Keywords

palliative, solid tumor, ascites

Brief summary

Current recommendations do not recommend the concomitant administration of albumin after ascites puncture in patients with ascites neoplasia unlike cirrhotic ascites. The etiology of ascites in cancer patients is multifactorial, particularly by hepatic invasion that can lead to ascites loaded with albumin. Ascites punctures therefore lead to undernutrition, recurrent early ascites by decreasing the oncotic pressure by hypo albuminemia and a state of anasarca affecting the quality of life.

Detailed description

According to the recommendations, each ascites fluid must be sent for biochemical and bacteriological analysis. Demonstrate the high gradient proportion (percent only, no threshold of significance required). The literature has already validated the importance of supplementing albumen with cirrhotic ascites. Demonstrating that some cancer patients have high gradients, this will be enough to make the practitioner think to supplement.

Interventions

DIAGNOSTIC_TESTcirrhotic albumin

Ascites puncture

DIAGNOSTIC_TESTserum albumin

blood punctures

Sponsors

Institut Paoli-Calmettes
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patient over 18 years of age followed for a solid cancer in a palliative metastatic situation who had a puncture of ascites.

Exclusion criteria

* Minor patient * Known cirrhosis

Design outcomes

Primary

MeasureTime frameDescription
Serum-Ascites Albumin Gradient Prevalence3 monthsElevated Serum-Ascites Albumin Gradient Prevalence in Palliative Cancer Patients

Secondary

MeasureTime frameDescription
Metastatic sites3 monthsNumber of Metastatic sites of patients with a high gradient.

Countries

France

Contacts

Primary ContactAurélien PROUX
PROUXA@ipc.unicancer.fr0491227643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026